Top 5 Drug Products Advertised in Professional Health Journals (Dollars) from January-February 2013

by Client Services

Xarelto and Tudorza Pressair are the products with the highest amount of money spent for professional journal ad campaigns year-to-date, according to Kantar Media. While Xarelto ranked #2 this time in 2012, Tudorza Pressair was only just approved by the FDA to treat chronic obstructive pulmonary disease last July.

Top 5 Print Ad Drugs (Dollars) Jan. – Feb. 2013

#1 Xarelto Tablets- $3 MM (+26%)

#2 Tudorza Pressair Inhalation Powder - $3 MM (N/A)

#3 Linzess Capsules - $3 MM (N/A)

#4 Zytiga - $938,000 (+102%)

#5 Qsymia Extended Release Capsules - $845,000 (N/A)

Linzess and Qsymia are also newcomers to the list compared to this time last year. Linzess received approval from the FDA in August 2012 for the treatment of adults with irritable bowel syndrome with constipation and for adults with chronic idiopathic constipation. Qsymia was approved by the FDA in July 2012 as an addition to a reduced-calorie diet and exercise for chronic weight management.

For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.